<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Edrophonium</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01010</strong>&#160; (APRD00944)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01010/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01010/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01010.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01010.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01010.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01010.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01010.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01010">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>3-hydroxy-N,N-dimethyl-N-ethylanilinium</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>EDR</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Edrophonium Ion</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-ethyl-3-hydroxy-N,N-dimethylanilinium</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Edrophonium Chloride</strong>
          <div class="cas">116-38-1</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000475/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000475/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: BXKDSDJJOVIHMX-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 201.092041846</li>
              <li>Average Mass: 201.693</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000475">DBSALT000475</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Antirex</td><td>Kyorin</td></tr><tr><td>Enlon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enlon Plus</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Reversol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tensilon</td><td>Roche</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/cholinesterase-inhibitors">Cholinesterase Inhibitors</a></li>
<li><a href="/mesh/antidotes">Antidotes</a></li></ul></td></tr><tr><th>CAS number</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Weight</th><td>Average: 166.2401<br>Monoisotopic: 166.123189139</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>16</sub>NO</td></tr><tr><th>InChI Key</th><td>VWLHWLSRQJQWRG-UHFFFAOYSA-O</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-ethyl-3-hydroxy-N,N-dimethylanilinium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC[N+](C)(C)C1=CC(O)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenols and Derivatives</td></tr><tr><th>Direct parent</th><td>Aminophenols</td></tr><tr><th>Alternative parents</th><td>Polyamines; Enols</td></tr><tr><th>Substituents</th><td>enol; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminophenols. These are organic compounds containing an amino group attached to a phenol.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.</td></tr><tr><th>Pharmacodynamics</th><td>Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Nicotinic acetylcholine (nAChR)receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the nicotinic acetylcholine receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetylcholine allow the remaining receptors to function more efficiently.</td></tr><tr><th>Mechanism of action</th><td>Edrophonium works by prolonging the action acetylcholine, which is found naturally in the body. It does this by inhibiting the action of the enzyme acetylcholinesterase. Acetylcholine stimulates nicotinic and muscarinic receptors. When stimulated, these receptors have a range of effects.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.6&#177;0.4 L/kg [Adults]</li>
	<li>2.2&#177;1.5 L/kg [Children (0.08-10 yrs)]</li>
	<li>1.8&#177;1.2 L/kg [Elderly (65-75 yrs)]</li>
</ul></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine.
Hepatic metabolism and biliary excretion have also been demonstrated in animals</td></tr><tr><th>Half life</th><td>Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.</td></tr><tr><th>Clearance</th><td><ul>
	<li>6.8 +/- 2. mL/kg/min [Adults]</li>
	<li>6.4 +/- 3.9 mL/kg/min [Children (0.08-10 yrs)]</li>
	<li>2.9 +/- 1.9 mL/kg/min [Elderly (65-75 yrs)]</li>
</ul></td></tr><tr><th>Toxicity</th><td>With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8406</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6827</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6628</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9814</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9163</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8132</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7682</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6247</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.569</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9181</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9523</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9202</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.6723
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.5357
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.903
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4293 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8461
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6585
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hospira inc</li>
<li>Watson laboratories inc</li>
<li>Bioniche pharma usa llc</li>
<li>Organon usa inc</li>
<li>Valeant pharmaceuticals international</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li>Taylor Pharmaceuticals</li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intramuscular</td><td></td></tr><tr><td>Liquid</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Edrophonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>